[go: up one dir, main page]

BR9707049A - Agentes anticoagulantes utilizáveis no tratamento de trombose - Google Patents

Agentes anticoagulantes utilizáveis no tratamento de trombose

Info

Publication number
BR9707049A
BR9707049A BR9707049-1A BR9707049A BR9707049A BR 9707049 A BR9707049 A BR 9707049A BR 9707049 A BR9707049 A BR 9707049A BR 9707049 A BR9707049 A BR 9707049A
Authority
BR
Brazil
Prior art keywords
thrombosis
treatment
anticoagulant agents
agents usable
anticoagulant
Prior art date
Application number
BR9707049-1A
Other languages
English (en)
Inventor
Michael Neal Blackburn
William Robert Church
Giora Zeev Feuerstein
Mitchell Stuart Gross
Andrew John Nichols
Eduardo Agustin Padlan
Arunbhai Haribhai Patel
Daniel Robert Sylvester
Original Assignee
Smithkline Bechecham Corp
Univ Vermint And State Agricul
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Bechecham Corp, Univ Vermint And State Agricul filed Critical Smithkline Bechecham Corp
Publication of BR9707049A publication Critical patent/BR9707049A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"AGENTES ANTICOAGULANTES UTILIZáVEIS NO TRATAMENTO DE TROMBOSE" Anticorpos monoclonais dirigidos contra fatores de coagulação e seu uso na inibição de trombose são descritos.
BR9707049-1A 1996-01-17 1997-01-17 Agentes anticoagulantes utilizáveis no tratamento de trombose BR9707049A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1010896P 1996-01-17 1996-01-17
US2911996P 1996-10-24 1996-10-24
PCT/US1997/000759 WO1997026010A1 (en) 1996-01-17 1997-01-17 Anticoagulant agents useful in treatment of thrombosis

Publications (1)

Publication Number Publication Date
BR9707049A true BR9707049A (pt) 2000-10-24

Family

ID=26680794

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9707049-1A BR9707049A (pt) 1996-01-17 1997-01-17 Agentes anticoagulantes utilizáveis no tratamento de trombose

Country Status (25)

Country Link
US (5) US6005091A (pt)
EP (2) EP1832297A1 (pt)
JP (2) JP2000503210A (pt)
KR (1) KR100553629B1 (pt)
CN (1) CN1213312A (pt)
AR (1) AR005658A1 (pt)
AT (1) ATE330630T1 (pt)
AU (1) AU706397B2 (pt)
BR (1) BR9707049A (pt)
CZ (1) CZ299452B6 (pt)
DE (1) DE69736197T2 (pt)
DK (1) DK1007089T3 (pt)
ES (1) ES2267131T3 (pt)
HU (1) HU225903B1 (pt)
ID (1) ID17156A (pt)
IL (1) IL125380A0 (pt)
MA (1) MA24512A1 (pt)
MX (1) MX9805810A (pt)
NO (1) NO983284L (pt)
NZ (2) NZ331014A (pt)
PL (1) PL187274B1 (pt)
PT (1) PT1007089E (pt)
SI (1) SI1007089T1 (pt)
TR (1) TR199801390T2 (pt)
WO (1) WO1997026010A1 (pt)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US20040038898A1 (en) * 1996-05-16 2004-02-26 The Trustees Of Columbia University Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
CA2294833A1 (en) * 1997-07-03 1999-01-14 Smithkline Beecham Corporation Crystal structures of anti-factor ix fab fragments and methods of use for peptidomimetic design
DE19802139C1 (de) * 1998-01-22 1999-09-23 Centeon Pharma Gmbh Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung
CA2327587C (en) * 1998-05-08 2011-09-13 Stichting Sanquin Bloedvoorziening Methods for treatment of haemophilia a patients using human anti-human fviii antibodies
US7250494B2 (en) 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
CA2341276C (en) 1998-08-28 2005-10-11 Genentech, Inc. Human anti-factor ix/ixa antibodies
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
JP4803879B2 (ja) * 1998-10-31 2011-10-26 アメリカ合衆国 ヒト化抗−癌腫モノクローナル抗体ｃｃ４９
AU781638B2 (en) * 1999-07-14 2005-06-02 D. Collen Research Foudation Vzw Ligands for use in therapeutic compositions for the treatment of hemostasis disorders
US7829085B2 (en) * 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
US7067313B1 (en) 1999-07-14 2006-06-27 D. Collen Research Foundation Ligands for use in therapeutic compositions for the treatment of hemostasis disorders
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
US6316259B1 (en) * 2000-01-21 2001-11-13 Isis Pharmaceuticals, Inc. Antisense inhibition of glycogen synthase kinase 3 alpha expression
CN100339132C (zh) * 2000-05-15 2007-09-26 史密丝克莱恩比彻姆公司 抗血栓剂
US7312325B2 (en) * 2000-09-26 2007-12-25 Duke University RNA aptamers and methods for identifying the same
ES2346189T3 (es) 2001-01-11 2010-10-13 Life Sciences Research Partners Vzw Metodo y composicion farmaceutica para prevenir y/o tratar el sindrome de respuesta inflamatoria generalizada.
CA2441228A1 (en) * 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
ES2316574T3 (es) * 2001-06-12 2009-04-16 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Anticuerpo de tipo humano contra el factor viii de la coagulacion sanguinea.
EP1416964A4 (en) * 2001-07-09 2005-10-12 Aphton Corp TREATMENT AND PREVENTION OF CANCER AND PRECANCEROUS DISEASES OF THE LIVER, LUNG AND ESOPHAGUS
WO2003013423A2 (en) * 2001-08-05 2003-02-20 Gvg, Inc. Antithrombotic agent
US20040052779A1 (en) * 2001-12-21 2004-03-18 Stinson Jeffrey R. Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
CA2490659C (en) 2002-06-28 2014-08-19 Syed V. S. Kashmiri Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
US6928528B1 (en) 2002-10-07 2005-08-09 Advanced Micro Devices, Inc. Guaranteed data synchronization
EP1608984A2 (en) * 2003-03-28 2005-12-28 Aphton Corporation Gastrin hormone immunoassays
JP4422430B2 (ja) 2003-05-14 2010-02-24 帝國製薬株式会社 エストロゲン及び／又はプロゲストゲン含有外用貼付剤
US7785594B2 (en) 2003-08-14 2010-08-31 Life Sciences Research Partners Vzw Factor VIII inhibitory antibodies with reduced glycosylation
WO2005021594A2 (en) 2003-08-29 2005-03-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use
US7297336B2 (en) 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
AU2003271174A1 (en) * 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
US20080075712A1 (en) * 2003-10-14 2008-03-27 Kunihiro Hattori Double Specific Antibodies Substituting For Functional Proteins
EP1730193A2 (en) * 2004-03-29 2006-12-13 Receptor Biologix, Inc. Monoclonal antibodies to gastrin hormone
EP1794586B1 (en) 2004-09-22 2013-01-30 Cancer Advances, Inc., Monoclonal antibodies to progastrin
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
IN2014DN10515A (pt) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
US20100322921A1 (en) * 2006-10-16 2010-12-23 Rekha Bansal METHOD OF INHIBITING COAGULATION ACTIVATION WITH HUMAN ANTI-FACTOR Va ANTIBODIES AND USE THEREOF
CA2704064A1 (en) 2007-09-13 2009-03-29 University Of Zurich Humanized antibodies against the .beta.-amyloid peptide
EP2527369A3 (en) * 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
JP5334319B2 (ja) 2007-09-26 2013-11-06 中外製薬株式会社 Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
WO2009049234A2 (en) * 2007-10-11 2009-04-16 Regents Of The University Of California Methods of treating coagulopathy
PL2297207T3 (pl) * 2008-06-19 2019-03-29 Prothix Bv Zastosowanie przeciwciał przeciw czynnikowi XI do zapobiegania lub leczenia tworzenia skrzepliny
KR101962483B1 (ko) 2010-11-17 2019-03-29 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
JP6449777B2 (ja) 2012-12-21 2019-01-09 シアトル ジェネティックス， インコーポレイテッド 抗ｎｔｂ−ａ抗体ならびに関連する組成物および方法
WO2014160088A2 (en) * 2013-03-14 2014-10-02 Rhode Island Hospital, A Lifespan-Partner Treating hepatitis b virus infections
RU2730594C2 (ru) 2013-09-27 2020-08-24 Чугаи Сейяку Кабусики Кайся Способ получения полипептидного гетеромультимера
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
SG11201700473QA (en) 2014-08-07 2017-02-27 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
EP3279216A4 (en) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha PROCESS FOR PREPARING POLYPEPTIDE HETERO OLIGOMER
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
AU2016297018B9 (en) * 2015-07-21 2022-12-01 Takeda Pharmaceutical Company Limited A monoclonal antibody inhibitor of factor XIIa
WO2017110980A1 (ja) 2015-12-25 2017-06-29 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
CN108368166B (zh) 2015-12-28 2023-03-28 中外制药株式会社 提高含fc区多肽纯化效率的方法
CN108884169B (zh) 2016-01-22 2022-03-22 默沙东公司 抗凝血因子xi抗体
NZ746002A (en) 2016-04-28 2025-08-29 Chugai Pharmaceutical Co Ltd Antibody-containing preparation
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
CN109476758B (zh) 2016-06-14 2023-05-23 默沙东有限责任公司 抗-凝血因子xi抗体
EP3509637B1 (en) 2016-09-06 2024-11-27 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
AU2017363309A1 (en) * 2016-11-23 2019-07-11 Bioverativ Therapeutics Inc. Mono- and bispecific antibodies binding to coagulation factor IX and coagulation factor X
CA3048157A1 (en) * 2016-12-23 2018-06-28 Novartis Ag Methods of treatment with anti-factor xi/xia antibodies
KR102616666B1 (ko) 2016-12-23 2023-12-27 노파르티스 아게 인자 xi 항체 및 사용 방법
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
CA3066756A1 (en) 2017-06-15 2018-12-20 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
GB201709970D0 (en) * 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
BR112020005834A2 (pt) 2017-09-29 2020-09-24 Chugai Seiyaku Kabushiki Kaisha molécula multiespecífica de ligação ao antígeno tendo atividade de substituição de função de cofator do fator viii de coagulação sanguínea (fviii), e formulação farmacêutica contendo a referida molécula como ingrediente ativo
CN119161488A (zh) 2017-11-01 2024-12-20 中外制药株式会社 具有降低的生物活性的抗体变体和同种型
JP7530362B2 (ja) 2018-12-21 2024-08-07 カイマブ・リミテッド 共通の軽鎖を有するＦＩＸａ×ＦＸ二重特異性抗体
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3909799A1 (de) * 1989-03-24 1990-09-27 Behringwerke Ag Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2049655C (en) * 1990-09-17 1996-11-12 Akio Odawara Pharmaceutical composition for inhibiting platelet aggregation
WO1993009804A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
US5383928A (en) * 1992-06-10 1995-01-24 Emory University Stent sheath for local drug delivery
DK0658168T3 (da) * 1992-08-27 2001-01-22 Sanquin Bloedvoorziening Antistoffer, som er specifikke for et hæmostatisk protein, anvendelse heraf til isolering af intakt protein, hæmostatiske p
US5397581A (en) * 1993-02-05 1995-03-14 Lerman; Russell E. Means for continuous confectionery coating of edible centers
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US20070190059A1 (en) * 1996-01-17 2007-08-16 Smithkline Beecham Corporation Antithrombotic agents

Also Published As

Publication number Publication date
MA24512A1 (fr) 1998-12-31
AU706397B2 (en) 1999-06-17
AU1830897A (en) 1997-08-11
MX9805810A (es) 1998-11-30
HUP9900396A3 (en) 2001-10-29
PL187274B1 (pl) 2004-06-30
DE69736197D1 (de) 2006-08-03
ID17156A (id) 1997-12-04
US6391299B1 (en) 2002-05-21
CZ299452B6 (cs) 2008-07-30
ATE330630T1 (de) 2006-07-15
NO983284D0 (no) 1998-07-16
EP1007089A1 (en) 2000-06-14
CN1213312A (zh) 1999-04-07
CZ222598A3 (cs) 2000-01-12
SI1007089T1 (sl) 2006-12-31
HK1029513A1 (en) 2001-04-06
NZ331014A (en) 2000-01-28
US20070224198A1 (en) 2007-09-27
DK1007089T3 (da) 2006-10-09
HUP9900396A2 (hu) 1999-05-28
IL125380A0 (en) 1999-03-12
PL327929A1 (en) 1999-01-04
HU225903B1 (en) 2007-12-28
TR199801390T2 (xx) 1998-12-21
PT1007089E (pt) 2006-11-30
DE69736197T2 (de) 2007-06-21
EP1832297A1 (en) 2007-09-12
KR100553629B1 (ko) 2006-10-04
EP1007089B1 (en) 2006-06-21
WO1997026010A1 (en) 1997-07-24
ES2267131T3 (es) 2007-03-01
JP2007325602A (ja) 2007-12-20
AR005658A1 (es) 1999-07-14
EP1007089A4 (en) 2003-04-16
NZ501215A (en) 2001-04-27
JP2000503210A (ja) 2000-03-21
NO983284L (no) 1998-09-16
KR19990077329A (ko) 1999-10-25
US20020146411A1 (en) 2002-10-10
US6005091A (en) 1999-12-21
US20070003553A1 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
BR9707049A (pt) Agentes anticoagulantes utilizáveis no tratamento de trombose
FI955315A0 (fi) HIV:n proteaasin inhibiittoreita, jotka ovat käyttökelpoisia AIDS'n hoitoon
AR001811A1 (es) Anticuerpos anti-icam-1 modificados y su uso en eltratamiento de inflamaciones
DE59711218D1 (de) Verwendung von wasserlöslichen oder in wasser dispergierbaren vernetzten stickstoffhaltigen verbindungen in wasch- und reinigungsmitteln
ES2101499T3 (es) Fibras.
CY2006007I2 (el) Χρηση αναστολεων cgmp-φωσφοδιεστερασης στην αγωγη της ανικανοτητας
FI891716A7 (fi) HIV-proteaasi-inhibiittoreita, jotka ovat käyttökelpoisia AIDS'in hoidossa
TR28718A (tr) Dinamik takilan tipte cocuk bezi.
MX9707570A (es) Utilizacion de agonistas de alta1l para el tratamiento de la incontinencia urinaria.
ATE250625T1 (de) IM WESENTLICHEN REINES ZONULIN ALS PHYSIOLOGISCHER MODULATOR VON ßTIGHT JUNCTIONSß BEI SÄUGERN
DE69630955D1 (de) Immortalisierung bzw. desimmortalisierung von zellen
BR0009767A (pt) Agentes inibitórios e quimiotáticos derivados de osteopontina e seus usos
DE69814100D1 (de) Verschluss von absorbierenden artikeln
ATE262537T1 (de) Proliferationsinhibitor von endothellzellen und dessen verwendung
TR199802704T2 (xx) H�V tedavisinde Vx478, Zidov�din, FTC ve/veya 3TC i�eren kombinasyonlar�n kullan�m�.
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
BR9405606A (pt) Uso de amidoaminas em composições oftálmicas
BR0110902A (pt) Inibidores de mmp-9/mmp-2
ATE71149T1 (de) Monoklonale antikoerper.
SE8502540L (sv) Stabilt tandvardsmedel innehallande dextranas
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
NO20011901L (no) Antikonvulsive derivater nyttige ved behandling av alkoholavhengighet og -misbruk
DE69109539D1 (de) Verminderung und Inhibition des Gehalts von Äthylenthioharnstoff in Alkylenbisdithiocarbamaten.
UA26438A (uk) СПОСІБ ОТРИМАHHЯ СУЛЬФОHІЛФЕHІЛ- БЕttА-D-ТІОКСИЛОЗИДІВ
ECSP972005A (es) Agentes anticoagulantes utiles en el tratamiento de trombosis

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
HKFN Application deemed withdrawn (deleted)
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: ENTENDE-SE QUE A MATERIA REQUERIDA NAO ATENDE AOS REQUISITOS DE PATENTEABILIDADE DE ACORDO COM OS ARTIGOS 8O C/C 13 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]